PEGBIO CO-B

PegBio opened lower and rallied sharply in the morning session, surging from HK$6.63 to HK$6.905 within the first two minutes, up 5.02%, driven by news that its GLP-1 drug has entered clinical use. The company remains pre-revenue, with Q4 net loss of HK$63.8 million, narrowing 6.14% YoY, but profitability still distant. The stock is 91.03% below its 52-week high of HK$77 and down 90.03% YTD, though it has crossed above the MA20 (HK$6.244) while trailing the MA60 (HK$7.597), reflecting short-term momentum against a still-bearish medium-term trend.

PegBio staged a strong afternoon rally, closing up 5.0% at HKD 5.585, driven by persistent positive sentiment from last week's partnership with Rani Therapeutics to develop oral metabolic disease drugs. The company remains in a loss-making phase, with Q4 2025 net loss of HKD 63.8 million (narrowing 6.14% YoY), yet PB stands at 4.4x. The stock is 92.75% below its 52-week high of HKD 77, and trades below both the 20-day MA (HKD 6.17) and 60-day MA (HKD 7.79), indicating long-term price weakness. However, today's turnover reached HKD 27.4 million with a turnover rate of 1.31%, and the price rebounded from an intraday low of HKD 5.330 to close at the day's high, reflecting short-term sentiment improvement.

PegBio-B closed 4.94% lower at HKD 5.31 after an intraday high of HKD 5.74, reversing its morning gain. The stock has shed over 20% from its 31% surge in late July on the Rani Therapeutics oral metabolic therapy partnership, as profit concerns persist. Q4 2025 operating loss was HKD 63.1 million, narrowing only 3.32% YoY, with net loss of HKD 63.8 million. Current market cap stands at ~HKD 2.08 billion, with a PB of 4.18x, and the stock remains well below its 52-week highs, underperforming the broader market. The Rani deal, while a long-term catalyst, has yet to improve near-term fundamentals.

PegBio opened the morning session on a strong note, with the opening price of HKD 5.395 serving as the intraday low before a rapid rally to a morning high of HKD 5.660, representing a gain of approximately 5.0% from the previous close of HKD 5.390, and closing at HKD 5.660 on volume of over 880,000 shares. The positive momentum was driven by continued market digestion of yesterday's partnership announcement with Rani Therapeutics to develop oral metabolic disease therapies, a deal that had previously triggered a 31% single-day surge, though today's gains were more moderate as investors assess the company's expanding global GLP-1 pipeline potential. However, the company remains fundamentally loss-making, with a net loss of approximately HKD 63.8 million in Q4 2025, only a 6.14% year-on-year improvement, and currently generates no operating revenue. The stock remains 92.6% below its 52-week high of HKD 77, with a market cap of ~HKD 2.2 billion, PB of 4.46x, and both MA20 (HKD 6.263) and MA60 (HKD 8.723) trading above the current price, indicating continued technical weakness.

PegBio-B fell intraday to close at HKD 5.45, down 7.63% from prior close of 5.90, with volume of 5.84M shares and turnover of HKD 33.01M. The stock initially surged to an intraday high of 5.95 in the morning session but steadily declined, hitting a low of 5.39 in the afternoon and settling near the session trough. The decline follows a two-day rally of over 31% after the company's collaboration with Rani Therapeutics on oral metabolic therapies, with profit-taking now erasing part of those gains. The company remains in a loss-making phase: Q4 2025 reported a loss per share of HKD -0.1651, net loss of HKD 63.80M, though the loss narrowed 6.14% from Q3, but zero operating revenue persists. At HKD 5.45, the stock is 92.92% below its 52-week high of 77.00, down 92.13% year-to-date, and well below its MA20 (6.286) and MA60 (9.764), indicating sustained price weakness. However, it trades only 10.32% above its 52-week low of 4.94, suggesting a potential near-term floor.